New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT06716138
Summary
This is the first study in humans testing a new drug called ANS03 for people with advanced solid tumors that have specific genetic changes (ROS1 or NTRK). The main goals are to check the drug's safety, how the body processes it, and look for early signs that it might help control the cancer. The study will enroll 96 adults with advanced cancer that has spread or cannot be removed by surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS HARBORING A ROS1 OR NTRK ALTERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10022, United States
-
Research Site
RECRUITINGFuzhou, Fujian, China
-
Research Site
RECRUITINGGuangzhou, Guangdong, China
-
Research Site
RECRUITINGShanghai, Shanghai Municipality, China
-
Research Site
RECRUITINGChengdu, Sichuan, China
Conditions
Explore the condition pages connected to this study.